大健康产业是关乎民生福祉、承载经济转型希望的新兴产业,也是聊城市重点打造的4条标志性产业链之 一。2025年以来,全市以《聊城市大健康产业发展规划(2024—2028年)》为蓝图,聚焦医药制品、健康食 品、医疗器械三大领域,将品牌建设作为核心引擎,着力推动产业链从"单点突破"向"集群协同"升级,从"传 统制造"向"高端智造"跨越。 目前,全市大健康产业链规上企业达52家,2025年实现产值114.5亿元,同比增长9.8%；营业收入102.7亿元, 同比增长6.2%；利润总额20.3亿元,同比增长13.2%,呈现出稳健向上的发展态势。特别值得一提的是,东 阿阿胶（000423）、冠县灵芝产业集群先后入选省级医养健康特色产业集群；全市大健康产业集群入选 省"十强产业"雁阵形产业集群储备库；聊城市参与联合申报的沿黄中医药产业集群入选省"十强产业"支 柱型雁阵集群,品牌赋能的叠加效应持续释放。 聊城市卫生健康委员会举行"品牌赋能大健康产业高质量融合发展"主题发布会,聊城市计划生育协会副 会长、大健康产业链专班办公室主任纪浩晴介绍了聊城市大健康产业链发展的有关情况。 陶春燕 聊城报道 构建品牌矩阵 筑牢产业发展"金招牌 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） 控股子公司赛诺神畅医疗科技有限 公司（以下简称"赛诺神畅"）于2024年向欧盟公告机构递交了公司Ghunter颅内取栓支架按照欧盟医疗 器械法规Medical Devices Regulation（EU）2017/745（简称"MDR"）注册认证的申报资料。赛诺神畅于 近日收到欧盟公告机构通知，Ghunter颅内取栓支架获得按照欧盟MDR法规签发的欧盟CE MDR认证。 现将相关情况公告如下： 一、注册证内容 证书名称：EU Quality Management System Certificate、 证书编号：2291466TD01, 2291466CE01 EU Technical Documentation Assessment Certificate 二、医疗器械基本情况 本次获得欧盟公告机构批准的Ghunter颅内取栓支架，是赛诺神畅自主研发的一款急性缺血类产品。全 显影设计，增加手术过 ...

Financial Performance - For the full year 2025, the company reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, growing 30.8% [5][24] - In Q4 2025, revenue totaled $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a growth of 52.1% [6][25] - The base business revenue for Q4 was $726.7 million, growing 10.6% year-over-year, with a consolidated Adjusted EBITDA margin of 33.9% [6][25] Business Line Performance - The U.S. spine business grew 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [7][28] - Enabling Technologies revenue reached $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][27] - The trauma business delivered approximately 27% growth in Q4, supported by the uptake of the legacy trauma line and new product launches [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed incremental improvement, culminating in a record sales quarter in Q4 2025 [29][28] - Growth in international markets was led by enabling technologies and the spine business, particularly in the UK, Australia, Germany, Brazil, Mexico, and Poland [28] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base, with a focus on innovation in product development [15][18] - The integration of Nevro is expected to enhance the company's portfolio, allowing entry into adjacent markets while driving differentiation in legacy businesses [18][17] - The company remains competitive in the evolving market landscape, emphasizing the unique capabilities of its ExcelsiusGPS platform [12][14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and an expanded sales force as key drivers [70] - The company anticipates continued margin expansion, with a target of achieving a gross profit margin in the range of 69%-70% for 2026 [32][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates as the year progresses [81][80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a new share repurchase program of $500 million announced [38][39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36][43] - The company achieved $200 million in synergies from the NuVasive acquisition, exceeding initial targets [41][42] Q&A Session Summary Question: Can you bridge the growth expectations for the base business from 2025 to 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How did the company perform in terms of market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market, with evidence from consistent growth rates [56][57] Question: What contributed to the recovery in enabling technology performance? - Management indicated that the fourth quarter saw a closure of delayed pipeline deals, contributing to the improved performance [62][63] Question: How sustainable is the U.S. spine growth, especially with new competition? - Management expressed confidence in the durability of U.S. spine growth, emphasizing ongoing product launches and competitive strategies [70][71] Question: What are the challenges and growth prospects for the international business? - Management highlighted the potential for 12%-15% growth in international markets, focusing on deeper penetration rather than expansion into new countries [81][80]

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, up 30.8% [6][24] - In Q4 2025, revenue reached $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a 52.1% increase [7][25] - The adjusted gross margin for Q4 was 69.2%, compared to 67.1% in the prior year quarter, driven by favorable sales mix and synergy execution [30][31] Business Line Performance - The U.S. spine business grew 10% in Q4 2025 compared to the prior year quarter, continuing a trend of above-market growth [8][28] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [12][27] - The trauma business delivered approximately 27% growth in Q4, supported by the legacy trauma line and new product launches [16][17] Market Performance - U.S. revenue in Q4 2025 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [29][83] Company Strategy and Industry Competition - The company aims to expand its core spine business while growing other segments, positioning itself as a procedure-enabling medtech platform integrating imaging, navigation, robotics, and implants [19][20] - The competitive landscape is evolving, with new robotic navigation systems entering the market, but the company believes its ExcelsiusGPS system remains a strong option for customers [13][73] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustained growth momentum, particularly in the U.S. spine business, and anticipates continued above-market growth in 2026 [9][71] - The company expects to achieve a full-year adjusted gross margin of 69%-70% in 2026, reflecting ongoing improvements in manufacturing initiatives [32][43] Other Important Information - The company repurchased approximately 4.3 million shares for $300.5 million during 2025, with a new share repurchase program of $500 million announced [39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [58] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [62][63] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [71][72] Question: What are the headwinds in the international market? - Management identified challenges in the APAC region, particularly Japan, but believes there are ample opportunities for growth in existing markets [82][83]

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAidan Lahey - Equity Research AssociateBrian G. Lloyd - Chief Legal Officer and Corporate SecretaryMartha Aronson - President and CEORaul Parra - CFO and TreasurerConference Call ParticipantsDavid Rescott - Director and Senior Research AnalystJason Bednar - Managing Director and Senior Research AnalystJayson Bedford - Managing Director and Senior AnalystJim Sidoti - Senior Equity AnalystJohn Young - ...

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker10Welcome to the Merit Medical Systems fourth quarter 2025 earnings conference call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aaronson, Merit Medical Systems President and Chief Executive Officer. ...

Core Insights - The Chinese medical device industry has undergone significant transformation since the country joined the WTO in 2001, leading to the establishment of a comprehensive network of sales, service, and training by multinational manufacturers [1][2] - The domestic production of medical devices has increased dramatically, with the localization rate of monitoring devices exceeding 85%, and the market share of Chinese medical devices in the global market is on the rise [2][3] - China's medical device sector is projected to grow, with over 35,000 production companies expected by the end of 2025 and a market size estimated to reach 1.22 trillion yuan [2] Industry Development - The medical device sector is a crucial pillar of healthcare, alongside medical services and pharmaceuticals, encompassing a wide range of products including diagnostic equipment and implants [1] - The emergence of numerous startups focused on independent research and development of medical devices has been driven by market demand [1] - The Chinese manufacturing industry has developed capabilities across nearly all categories of medical devices, with significant advancements in innovative products such as ECMO [3] Technological Advancements - The integration of advanced technologies such as artificial intelligence and 5G is expected to drive the next wave of innovation in medical devices, enabling new diagnostic and treatment methods [4] - The establishment of research and development centers by foreign companies in China highlights the strategic importance of the local market and supply chain [3] Market Dynamics - China's large population and diverse health needs are accelerating the pace of technological iteration in the global medical device industry [2] - The shift from "following" to "competing" and even "leading" in certain areas reflects the industry's evolution and the rise of "China Intelligent Manufacturing" [3]

深圳开立生物医疗科技公司业务经理表示："依托班列的稳定服务和定制化方案，我们的精密医疗设备 才能安全、准时送达欧洲客户手中。" 平湖南综合物流枢纽营业部经理罗练林表示："我们将构建更高效、便捷的国际物流平台，进一步降低 企业跨境贸易的综合成本。" 本报深圳2月24日电(记者李刚)2026年农历正月初一早上8时许，一声汽笛在深圳平湖南站鸣响，满载家 电、电子产品及跨境电商包裹的X8426次中欧班列，迎着新春朝阳启程，奔赴满洲里口岸，预计14天后 抵达俄罗斯、波兰等国家。 这趟新春首发的中欧班列是粤港澳大湾区外贸物流"开年第一单"。自2020年8月18日首趟"湾区号"中欧 班列从深圳开往德国杜伊斯堡以来，截至目前已累计开行975列，运送货物超9万标箱，货值突破31亿美 元，线路从1条增至27条常态化线路，覆盖德国、俄罗斯等47个国家和地区，服务大湾区企业超7000 家。 ...

转自：贵州日报 2月24日，在山东省烟台市芝罘区只楚街道一家制冷设备和换热装置制造企业，工人在生产线上忙碌。 新华/传真 2月24日，正月初八，开工! 春节假期后首个工作日，多地以"新春第一会"吹响奋进号角，重大项目开工蹄疾步稳，企业生产线开足 马力赶订单、保供应，"十五五"开局之年，奋力跑出万马奔腾的昂扬气势。 凝心聚力，绘就全年"施工图" 正月初八，岭南春早。2026年广东省高质量发展大会如约而至，这是广东连续四年在春节后首个工作日 举办高质量发展大会。 从明确"再造一个新广东"的目标，到创新驱动、现代化产业体系建设，再到今年"制造业与服务业协同 发展"，广东"新春第一会"的主题年年深入，一以贯之推动高质量发展。 春节假期节后首日，多地"新春第一会"召开，以"开局即冲刺"的姿态绘就全年"施工图"，为高质量发展 部署"任务书"。 江淮腹地，合肥"新春第一会"聚焦"科技创新引领新质生产力发展"。科研人员、企业家、基层干部齐聚 一堂，共商创新之策。"'新春第一会'再次强调科技创新，让我们充满信心，新的一年企业将坚持以实 干争先，以创新赋能。"蔚来汽车创始人李斌说。 三湘大地，湖南省召开全省促进民营经济发展壮大暨 ...